Everfront Biotech Holding ^{Filed, US Offering, Nasdaq: EFB}

We value sustainable development and are committed to providing more promising treatment solutions for patients. Our mission is to construct effective strategies for combating hard-to-treat diseases such as glioblastoma (GBM), pancreatic cancer (PC), and amyotrophic lateral sclerosis (ALS). We designed the implantable Cerebraca Wafer for in-situ drug delivery. After surgical resection, implantation of the wafer at the tumor margin is designed to create a localized high drug concentration, targeting residual and or unresectable tumor cells. Additionally, the wafer’s sustained release technology is designed to facilitate continuous drug release within the brain for one month. We also developed soft-gel capsules designed to be easily swallowed as maintenance therapy following Cerebraca Wafer implantation. Furthermore, we are exploring the feasibility of expanding our treatment approach to pancreatic cancer. By establishing and directing the four product pipelines, we believe we will be able to achieve our goal. As of the date of this prospectus, we are conducting three clinical trials in Taiwan based on investigational new drug (IND) approvals from both the United States Food and Drug Administration (the “FDA”) and the Taiwan Food and Drug Administration (the “TFDA”). Additionally, we expect to submit an IND for EF-031 in the second quarter of 2025.